An inflammatory demyelinating condition known as multiple sclerosis affects the central nervous system and is characterised by remyelination failure, axonal degradation, and a progressive deterioration of motor skills. MS treatments are frequently developed and tested using animal models of demyelination. Acute motor impairments were caused by focal internal capsule demyelination in mice following Lysophosphatidylcholine injection, as we recently reported. These deficits were then resolved through remyelination. However, it is yet unclear whether behavioural testing and histological analysis can be utilised to assess changes in motor capabilities brought on by pharmacological therapies that encourage remyelination in the IC demyelination mouse model. In this study, we investigated the effects of clemastine in the mouse IC demyelination model, an anti-muscarinic medication that encourages remyelination. Administration of clemastine to the IC altered forepaw preference and improved motor function mice with demyelination
Share this article